Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
1999-08-20
2001-03-13
Hauda, Karen M. (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S003000, C800S009000
Reexamination Certificate
active
06201168
ABSTRACT:
BACKGROUND OF THE INVENTION
The sarcoglycan complex is a group of single pass transmembrane proteins (&agr;-, &bgr;-, &igr;- and &ggr;-sarcoglycan) which is tightly associated with sarcospan to form a subcomplex within the dystrophin-glycoprotein complex (DGC) in skeletal and cardiac muscle (Campbell et al.,
Nature
338: 259-362 (1989); Yoshida et al.,
J. Biochem
. 108: 748-752 (1990); Crosbie et al.,
J. Cell Biol
. 145: 153-165 (1999)). The DGC is further comprised of dystrophin, the dystroglycan complex and the syntrophins (Hoffman et al.,
Cell
51: 919-928 (1987); Froehner et al.,
Soc. Gen. Physiol. Ser
. 52: 197-207 (1997); Durbeej et al.,
Curr. Opin. Cell. Biol
. 10: 594-601 (1998)). The expression of the sarcoglycan-sarcospan complex is necessary to target dystroglycan to the sarcolemma (Duclos et al.,
J. Cell Biol
. 142: 1461-1471 (1998); Duclos et al.,
Neuromusc. Disord
. 8: 30-38 (1998); Holt et al.,
Mol. Cell
1: 841-848 (1998); Straub et al.,
Am. J. Path
. 153: 1623-1630 (1998)) which in turn confers a link between the extracellular matrix and the F-actin cytoskeleton (Ervasti et al.,
J. Cell Biol
. 122: 809-823 (1993)). Thus, the DGC is thought to protect muscle cells from contraction-induced damage (Petrof et al.,
Proc. Natl. Acad. Sci. USA
90: 3710-3714 (1993)). In agreement with this hypothesis, mutations in the genes for the sarcoglycans, dystrophin and laminin &agr;2 chain are responsible for limb-girdle muscular dystrophy, Duchenne/Becker muscular dystrophy and congenital muscular dystrophy respectively (Straub et al.,
Curr. Opin. Neurol
. 10: 168-175 (1997); Lim et al.,
Curr. Opin. Neurol
. 11: 443-452 (1998)). Clinical evidence of cardiomyopathy is variably present in these muscular dystrophies (Towbin, J. A.,
Curr. Opin. Cell Biol
. 10: 131-139 (1998)) but a correlation between the primary mutation of the sarcoglycan genes and cardiomyopathy is yet to be established (Melacini et al.,
Muscle & Nerve
22: 473-479 (1999)).
Dilated cardiomyopathy is a multifactorial disease that includes both inherited and acquired forms of cardiomyopathy. Inherited cardiomyopathy in humans can be associated with genetic defects occurring in components of the dystrophin-glycoprotein complex (DGC) (Towbin, J. A.,
Curr. Opin. Cell Biol
. 10: 131-139 (1998)). Mutations in the dystrophin gene lead to a high incidence of cardiomyopathy in Duchenne and Becker muscular dystrophy patients (DMD/BMD) and can cause X-linked dilated cardiomyopathy (Towbin, J. A.,
Curr. Opin. Cell Biol
. 10: 131-139 (1998)). In addition to these primary genetic causes of cardiomyopathy, recent data suggest that disruption of the DGC underlie the cardiomyopathy associated with enteroviral infection (Badorff et al.,
Nat. Med
. 5: 320-326 (1999)). Consequently, evidence is accumulating that the DGC plays a critical role in the pathogenesis of some forms of inherited and acquired cardiomyopathy. Several components of the DGC are also expressed in smooth muscle (Houzelstein et al.,
J. Cell Biol
. 119: 811-821 (1992); North et al.,
J. Cell Biol
. 120: 1159-1167 (1993); Ozawa, et al.,
Hum. Mol. Gen
. 4: 1711-1716 (1995); Durbeej et al.,
Curr. Opin. Cell. Biol
. 10: 594-601 (1998)). Interestingly, potential smooth muscle dysfunction has been described in patients with Duchenne muscular dystrophy (Bahron et al.,
N. Engl. J. Med
. 319: 15-18 (1998); Jaffe et al.,
Arch. Phys. Med. Rehabil
. 71: 742-744 (1990)). However, no smooth muscle dysfunction has been reported in patients with limb-girdle muscular dystrophy.
Recently, a fifth sarcoglycan, &egr;-sarcoglycan, was cloned and shown to be highly homologous to &agr;-sarcoglycan (Ettinger et al.,
J. Biol. Chem
. 272: 32534-32538 (1997); McNally et al.,
FEBS Lett
. 422: 27-32 (1998)). &egr;-sarcoglycan is expressed in skeletal and cardiac muscle, but also in several non-muscle tissues. Whether &egr;-sarcoglycan is associated with the other sarcoglycans in striated muscle is yet to be determined. At the immunofluorescence level, however, it has been shown that &egr;-sarcoglycan is still present in skeletal muscle of a-sarcoglycan deficient (Sgca-null mice) mice although the other sarcoglycans are greatly reduced (Duclos et al.,
J. Cell Biol
. 142: 1461-1471 (1998)). This indicates that &egr;-sarcoglycan is not an additional member of the known tetrameric complex of &agr;-, &bgr;-, &ggr;- and &dgr;-sarcoglycan in skeletal muscle but may be part of a distinct complex at the sarcolemma.
Sgca-null mice have recently been reported to display a progressive muscular dystrophy (Duclos et al.,
J. Cell Biol
. 142: 1461-1471 (1998)). The primary absence of &agr;-sarcoglycan was accompanied by the concomitant loss of &bgr;-,&ggr;- and &dgr;-sarcoglycan and sarcospan in skeletal and cardiac muscle fibers, a phenomenon that is also observed in human forms of sarcoglycanopathies (Lim et al.,
Curr. Opin. Neurol
. 11: 443-52 (1998)). Interestingly, although the SG-SSPN complex was absent from the cardiac muscle membrane, no morphological signs of cardiomyopathy were observed (Duclos et al.,
J. Cell Biol
. 142: 1461-1471 (1998)).
SUMMARY OF THE INVENTION
One aspect of the present invention relates to a mouse, and cells derived therefrom, which is homozygous for a disrupted &dgr;-sarcoglycan gene, the disruption in said gene having been introduced into the mouse or an ancestor of the mouse at an embryonic stage. Said disruption prevents the synthesis of functional &dgr;-sarcoglycan in cells of the mouse and results in the mouse having a reduced amount of &bgr;- and &egr;-sarcoglycan and sarcospan, and a disruption of the sarcoglycan-sarcospan complex in smooth muscle of the mouse. Said disruption also results in a reduced amount of sarcospan, &agr;-, &bgr;-, &bgr;-, and &egr;-sarcoglycan in the sarcolemma of skeletal and cardiac muscles of the mouse, compared to the amounts of said components in a mouse lacking disrupted &dgr;-sarcoglycan genes. Preferred specific disruptions of the &dgr;-sarcoglycan gene are listed.
Another aspect of the present invention relates to a mouse, and cells derived therefrom, which is homozygous for a disrupted &bgr;-sarcoglycan gene, the disruption in said gene having been introduced into the mouse or an ancestor of the mouse at an embryonic stage. The disruption prevents the synthesis of functional &bgr;-sarcoglycan in cells of the mouse and results in the mouse having a reduced amount of 6- and &egr;-sarcoglycan and sarcospan and &agr;-dystroglycan in smooth muscle of the mouse. The disruption also results in a disruption of the sarcoglycan-sarcospan complex in smooth muscle of the mouse, and a reduced amount of sarcospan, &agr;-, &ggr;-, &dgr;- and &egr;-sarcoglycan in the sarcolemma of skeletal and cardiac muscles of the mouse, compared to the amounts of the components in a mouse lacking disrupted &bgr;-sarcoglycan genes. Preferred specific disruptions of the &bgr;-sarcoglycan gene are listed.
Another aspect of the present invention is a method for treating mammalian autosomal recessive limb-girdle muscular dystrophy type 2F in an individual. The method comprises, providing an expression vector which encodes a wild-type form of &dgr;-sarcoglycan, and introducing the expression vector into skeletal and smooth muscle tissue of the individual under conditions appropriate for expression of the wild-type form of &dgr;-sarcoglycan in said tissues. Examples of expression vectors for use in this method are adenovirus expression vector, a gutted adenovirus expression vector, and an adeno-associated expression vector. In one embodiment, the expression vector contains a muscle tissue-specific promoter. One method of introduction into the skeletal muscle is by intramuscular injection.
Another aspect of the present invention is a method for treating mammalian autosomal recessive limb-girdle muscular dystrophy type 2E in an individual. The method comprises, providing an expression vector which encodes a wild-type form of &bgr;-sarcoglycan, and introducing the expression vector into skeletal and smooth muscle tissue of the individual und
Campbell Kevin P.
Cohn Ronald
Coral Ramon
Durbeej Madeleine
Williamson Roger
Farrell Kevin M.
Hauda Karen M.
Shukla Ram R.
University of Iowa Research Foundation
LandOfFree
Pathogenesis of cardiomyopathy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pathogenesis of cardiomyopathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pathogenesis of cardiomyopathy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2500217